Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Operations (2016 - 2025)

Vanda Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 29417000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 1518.99% year-over-year to 29417000.0; the TTM value through Dec 2025 reached 109442000.0, down 594.56%, while the annual FY2025 figure was 109442000.0, 594.56% down from the prior year.
  • Cash from Operations for Q4 2025 was 29417000.0 at Vanda Pharmaceuticals, up from 31626000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 31803000.0 in Q1 2023 and bottomed at 33147000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 1114500.0 (2022), against an average of 810000.0.
  • The largest annual shift saw Cash from Operations skyrocketed 1113.56% in 2021 before it crashed 1518.99% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 26607000.0 in 2021, then crashed by 64.61% to 9416000.0 in 2022, then crashed by 139.63% to 3732000.0 in 2023, then soared by 51.31% to 1817000.0 in 2024, then plummeted by 1518.99% to 29417000.0 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Cash from Operations are 29417000.0 (Q4 2025), 31626000.0 (Q3 2025), and 15252000.0 (Q2 2025).